New hope for hard-to-treat breast cancer: experimental drug SYS6010 enters final testing phase
NCT ID NCT07406542
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called SYS6010 against standard chemotherapy in people with a specific type of advanced breast cancer (HER2-negative, EGFR-positive) that has come back or spread. About 400 adults who have already tried 1-2 chemotherapy treatments will be randomly assigned to get either SYS6010 or a standard chemo drug. The goal is to see if SYS6010 helps control the cancer longer without it growing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.